Typhoid Vaccine Market Size, Share, Growth, and Industry Analysis, By Types (Oral Type Typhoid Vaccine,Injection Type Typhoid Vaccine), By Applications (Hospital,Research & Academic Laboratories,Pharmaceutical & Biotechnology Companies,Others) , and Regional Insights and Forecast to 2035

Typhoid Vaccine Market Overview

Global Typhoid Vaccine Market size is projected at USD 11900  million in 2026 and is expected to hit USD 16791.4 million by 2035 with a CAGR of 3.9%.

The Typhoid Vaccine Market is expanding steadily due to the persistent global burden of typhoid fever and the increasing adoption of immunization programs in endemic regions. Globally, typhoid fever affects approximately 11 million to 20 million people each year and causes nearly 110,000 to 160,000 deaths annually, particularly across Asia and Africa. More than 35 million typhoid vaccine doses are distributed globally every year through national immunization campaigns and travel vaccination programs. The Typhoid Vaccine Market Research Report highlights growing adoption of typhoid conjugate vaccines (TCV), which demonstrate 79%–85% effectiveness in preventing infections in children. 

The United States Typhoid Vaccine Market Analysis indicates a specialized demand driven primarily by international travel vaccination and outbreak prevention programs. Approximately 5,700 typhoid fever cases are reported annually in the United States, with nearly 75% associated with international travel to endemic regions. More than 300,000 typhoid vaccine doses are administered annually through travel clinics, pharmacies, and public health centers. Injectable vaccines account for more than 60% of total vaccine administration due to their single-dose immunization schedule, while oral vaccines represent about 40% of vaccinations.

Download Free Sample to learn more about this report.

Key Findings

• Key Market Driver: More than 70% of global typhoid infections occur in South Asia, while approximately 55% of reported cases affect children under 15 years. Vaccination programs in over 25 countries have increased immunization coverage by nearly 40%, significantly driving Typhoid Vaccine Market Growth.
• Major Market Restraint: Around 30%–40% of low-income countries experience vaccine procurement limitations due to funding constraints, while nearly 20% of vaccine distribution programs face supply chain disruptions, limiting Typhoid Vaccine Market Share expansion in underdeveloped healthcare systems.
• Emerging Trends: Typhoid conjugate vaccines demonstrate prevention rates of approximately 79%–85%, while vaccine coverage campaigns have achieved 63%–95% immunization coverage among targeted populations, creating strong Typhoid Vaccine Market Opportunities across national immunization programs.
• Regional Leadership: Asia-Pacific accounts for nearly 55% of global vaccine demand, followed by Africa with about 20%, North America with approximately 10%, Europe with 8%, and the Middle East contributing roughly 7% of total Typhoid Vaccine Market Size distribution.
• Competitive Landscape: Nearly 70% of vaccine procurement globally occurs through government contracts and public health agencies, while approximately 30% of vaccines are distributed through private healthcare providers and travel immunization clinics.
• Market Segmentation: Injectable vaccines account for roughly 60% of administered doses, while oral vaccines represent nearly 40%. Public immunization programs contribute around 65% of vaccine demand compared with about 35% from private healthcare sectors.
• Recent Development: More than 75 million children have received typhoid conjugate vaccines through catch-up campaigns, with coverage levels reaching between 63% and 95% in several high-burden countries, accelerating Typhoid Vaccine Market Trends worldwide.

Typhoid Vaccine Market Latest Trends

The Typhoid Vaccine Market Trends are strongly influenced by the introduction and large-scale adoption of typhoid conjugate vaccines across national immunization programs. Demand for vaccines is increasing due to the high global incidence of typhoid fever, with approximately 11 million to 20 million cases reported annually. Governments in endemic regions are prioritizing immunization campaigns targeting children aged 6 months to 15 years, which represent more than 55% of typhoid infections globally. Global vaccination initiatives have resulted in more than 75 million children receiving typhoid conjugate vaccines through large-scale campaigns in Asia and Africa. 

Another key Typhoid Vaccine Market Insight involves improvements in vaccine supply chain management and production capacity. Manufacturing facilities across multiple countries are capable of producing between 5 million and 20 million vaccine doses annually to meet growing demand from immunization programs. Demand projections indicate routine vaccination requirements between 90 million and 100 million doses annually, with peak demand reaching nearly 300 million doses during mass vaccination campaigns. Technological advancements such as microarray patch vaccine delivery systems are also under development to expand vaccine access in remote regions and improve coverage among underserved populations, strengthening the long-term Typhoid Vaccine Market Outlook and global vaccination capacity. 

Typhoid Vaccine Market Dynamics

DRIVER

"Rising global incidence of typhoid infections"

The primary driver of the Typhoid Vaccine Market Growth is the increasing global incidence of typhoid fever and rising public health awareness regarding vaccine-based disease prevention. Typhoid fever affects between 11 million and 20 million people annually and causes approximately 110,000 to 160,000 deaths worldwide. Over 80% of infections occur in low- and middle-income countries across South Asia and Sub-Saharan Africa, where limited access to clean water and sanitation contributes to disease transmission. As a response, governments and global health organizations are expanding immunization programs targeting high-risk populations. 

RESTRAINTS

"Limited vaccine accessibility in low-income regions"

One of the major restraints affecting the Typhoid Vaccine Market Analysis is the limited accessibility of vaccines in low-income and resource-constrained regions. Many countries experiencing high disease burden still face healthcare infrastructure challenges, including insufficient cold chain storage capacity and limited vaccination workforce availability. Procurement costs and funding limitations also affect vaccine adoption in some national immunization programs. Despite global funding initiatives, supply forecasting remains uncertain due to variable country introduction timelines. Additionally, vaccine wastage rates historically reached approximately 15% in multi-dose vial programs before optimization efforts reduced wastage levels below 10%. 

OPPORTUNITY

"Expansion of national immunization programs"

Significant Typhoid Vaccine Market Opportunities are emerging through the expansion of national immunization programs and integration of typhoid vaccines into routine childhood vaccination schedules. Several countries with high disease prevalence are introducing typhoid conjugate vaccines into universal immunization programs targeting infants as young as six months of age. Routine vaccination demand is estimated to reach between 90 million and 100 million doses annually based on global birth cohorts across participating countries. Mass vaccination campaigns targeting children aged 6 months to 14 years are also contributing to large-scale vaccine procurement. 

CHALLENGE

"Supply chain and manufacturing capacity constraints"

Supply chain and manufacturing capacity constraints remain a key challenge impacting the Typhoid Vaccine Market Outlook. Vaccine manufacturers must maintain production capacity to meet large-scale immunization demand while ensuring strict regulatory compliance and quality control standards. Manufacturing facilities typically produce between 5 million and 20 million doses annually, which may not always meet the surge demand during mass vaccination campaigns. Global health agencies maintain emergency stockpiles of approximately 10 million doses to respond to outbreak situations within 72 hour.

Typhoid Vaccine Market Segmentation

The Typhoid Vaccine Market Segmentation is primarily categorized by type and application, reflecting the different delivery formats and end-use healthcare settings. By type, the market includes oral typhoid vaccines and injection type typhoid vaccines, both widely used for preventive immunization against Salmonella Typhi infections. Oral vaccines are commonly administered for travel immunization and preventive programs due to multi-dose capsule regimens, while injection vaccines are frequently used in public immunization campaigns and clinical settings. 

Download Free Sample to learn more about this report.

BY TYPE

Oral Type Typhoid Vaccine: Oral type typhoid vaccines represent a significant portion of the Typhoid Vaccine Market Share due to their convenient administration format and suitability for travel vaccination programs. These vaccines are typically delivered through capsules taken over multiple doses and provide immunity by stimulating mucosal immune responses in the intestinal tract. Clinical studies demonstrate that oral typhoid vaccines can provide protective immunity ranging between 60% and 70% among vaccinated populations. In global travel medicine programs, nearly 40% of travelers visiting typhoid-endemic regions receive oral vaccines as a preventive measure. The Typhoid Vaccine Market Research Report highlights that oral vaccines are particularly popular in North America and Europe, where international travel vaccination services operate through pharmacies and travel clinics. Approximately 75% of typhoid infections reported in developed countries originate from travelers returning from high-risk regions such as South Asia and Southeast Asia. 

Injection Type Typhoid Vaccine: Injection type typhoid vaccines dominate the Typhoid Vaccine Market Size due to their single-dose immunization capability, higher efficacy rates, and extensive use in government immunization programs. These vaccines are typically administered through intramuscular or subcutaneous injection and contain purified Vi polysaccharide or conjugate antigen formulations designed to stimulate a strong immune response. Injection vaccines account for approximately 60% of total typhoid vaccine administration globally, largely driven by large-scale immunization campaigns in endemic countries. Typhoid conjugate vaccines delivered through injection provide long-lasting protection and demonstrate effectiveness levels ranging between 79% and 85%. These vaccines can be administered to infants as young as six months old, which allows integration into routine childhood immunization schedules in high-risk regions. 

BY APPLICATION

Hospital: Hospitals represent one of the most important application segments within the Typhoid Vaccine Market Insights because they serve as primary vaccination centers for both preventive immunization and outbreak response programs. Hospital-based vaccination services administer a large proportion of injectable typhoid vaccines due to the availability of trained healthcare professionals and proper cold-chain storage systems. In many countries, hospitals account for nearly 40% of total typhoid vaccine administration across urban healthcare systems. Large tertiary hospitals often maintain vaccination units capable of administering thousands of vaccines each month. In regions experiencing frequent typhoid outbreaks, hospital vaccination campaigns are conducted for both pediatric and adult populations. More than 50% of hospitalized typhoid patients are children under the age of fifteen, prompting hospitals to prioritize pediatric vaccination initiatives. Hospitals also play a critical role in travel vaccination services. 

Research & Academic Laboratories: Research and academic laboratories contribute significantly to the Typhoid Vaccine Market Research Report by advancing vaccine development, clinical testing, and epidemiological research. Universities and public health research institutes conduct large-scale studies examining vaccine efficacy, immune response duration, and population-level disease control strategies. Many laboratories participate in multi-center clinical trials evaluating next-generation typhoid vaccines designed to improve protection rates and extend immunity duration. Clinical research programs often involve thousands of study participants across multiple countries where typhoid fever remains endemic. Vaccine efficacy trials conducted in these research laboratories demonstrate protective effectiveness ranging from 70% to 85% depending on vaccine formulation and population demographics. 

Pharmaceutical & Biotechnology Companies: Pharmaceutical and biotechnology companies represent a critical segment within the Typhoid Vaccine Market Outlook because they are responsible for vaccine manufacturing, product development, and large-scale distribution across global healthcare markets. These companies operate specialized vaccine production facilities capable of producing between several million and tens of millions of doses annually to meet growing global immunization demand. Manufacturing processes for typhoid vaccines involve advanced biotechnology techniques including bacterial fermentation, antigen purification, and conjugation technologies used in modern typhoid conjugate vaccines. Production facilities maintain strict regulatory standards and biosafety protocols to ensure vaccine safety and effectiveness. Global vaccine manufacturing networks supply vaccines to more than 25 countries participating in national typhoid immunization programs.

Others: The “Others” application segment within the Typhoid Vaccine Market Analysis includes community health centers, travel vaccination clinics, public health outreach programs, and international humanitarian organizations involved in disease prevention initiatives. These healthcare providers play a vital role in expanding vaccine accessibility beyond traditional hospital settings, particularly in rural and underserved communities. Community health centers administer large numbers of vaccines as part of routine immunization programs targeting children and high-risk populations. In many developing countries, community clinics serve as the primary vaccination point for populations living in remote areas where access to large hospitals is limited. Some vaccination campaigns conducted through community health networks immunize hundreds of thousands of individuals within a few weeks. Travel clinics represent another major contributor within this segment. 

Typhoid Vaccine Market Regional Outlook

The global typhoid vaccine market demonstrates a diversified regional distribution, collectively accounting for 100% market share across major geographic segments. Asia-Pacific dominates with approximately 45% market share due to high disease prevalence and large population base. North America holds around 20% share driven by strong immunization infrastructure and travel vaccination demand. Europe contributes nearly 15% supported by preventive healthcare policies. Middle East & Africa account for about 12% owing to endemic regions and growing immunization programs. The remaining 8% is distributed among smaller emerging markets. Each region shows varying adoption patterns influenced by healthcare access, awareness, and government initiatives, collectively shaping a balanced yet regionally skewed market landscape.

Download Free Sample to learn more about this report.

North America

North America represents a well-established segment of the typhoid vaccine market, contributing approximately 20% of the global market share. The region benefits from advanced healthcare systems, high awareness levels, and strong government-backed immunization programs. The United States accounts for the majority of the regional share, followed by Canada, due to higher international travel frequency and strict vaccination recommendations for travelers visiting endemic regions. Around 60% of typhoid vaccinations in North America are administered for travel purposes, reflecting the region’s proactive preventive healthcare approach. The market size in North America is driven by increasing outbound travel, particularly to Asia and Africa, where typhoid fever remains prevalent. Data suggests that more than 30 million international trips annually from North America involve destinations with moderate to high typhoid risk, directly supporting vaccine demand. Additionally, over 75% of travel clinics in the region routinely recommend typhoid vaccination as part of pre-travel consultations. 

Europe

Europe holds approximately 15% of the global typhoid vaccine market share, supported by well-organized healthcare systems and strong emphasis on preventive care. Countries such as France, Germany, and the United Kingdom collectively account for over 60% of the regional market. The demand is primarily driven by international travel, immigration patterns, and increasing awareness regarding infectious diseases. The region records nearly 25 million outbound travelers annually to typhoid-endemic regions, contributing significantly to vaccine demand. Around 65% of travel clinics across Europe recommend typhoid vaccination for high-risk destinations. Additionally, approximately 40% of vaccinations are administered through public healthcare systems, while private travel clinics contribute the remaining 60%. Injectable vaccines dominate the European market with about 70% share due to higher physician preference and established efficacy, while oral vaccines account for 30%. Adult vaccination constitutes nearly 80% of the demand, reflecting the travel-focused nature of the market. Europe also benefits from structured immunization policies and surveillance systems. 

Germany Typhoid Vaccine Market

Germany accounts for approximately 4% of the global typhoid vaccine market and nearly 25% of the European market share. The country’s strong healthcare infrastructure and high awareness levels contribute significantly to vaccine adoption. The demand is primarily driven by international travel, with over 10 million Germans traveling annually to regions where typhoid fever is endemic. Approximately 70% of typhoid vaccinations in Germany are administered through travel clinics, while general practitioners contribute around 30%. Injectable vaccines dominate the German market with nearly 75% share due to physician preference and established safety profiles. Oral vaccines hold the remaining 25%, mainly among younger travelers seeking convenience. Adult vaccination accounts for nearly 85% of the market, reflecting the travel-oriented demand pattern. Pediatric vaccination remains limited but is gradually increasing among families traveling abroad. Around 60% of travelers to high-risk regions receive pre-travel vaccination consultations, indicating strong preventive healthcare practices. Germany’s regulatory environment ensures high vaccine quality and availability, with widespread distribution across pharmacies and healthcare centers. 

United Kingdom Typhoid Vaccine Market

The United Kingdom contributes approximately 3.5% to the global typhoid vaccine market and around 20% within Europe. The market is largely driven by outbound travel, with nearly 7 million UK residents traveling annually to typhoid-endemic regions such as South Asia and Africa. Around 65% of vaccinations are administered through travel clinics, while the National Health Service (NHS) provides approximately 35% of vaccinations, particularly for high-risk individuals. Injectable vaccines dominate with about 70% market share, while oral vaccines account for 30%, reflecting patient preference for ease of use. Adult travelers represent nearly 80% of vaccine demand, while pediatric vaccination accounts for approximately 20%, primarily among families traveling abroad. The UK also demonstrates strong preventive healthcare practices, with nearly 60% of travelers seeking pre-travel medical advice. Public awareness campaigns and government recommendations play a crucial role in driving vaccine uptake. 

Asia-Pacific

Asia-Pacific dominates the global typhoid vaccine market with approximately 45% market share, driven by high disease prevalence and large population density. Countries such as India, China, and Southeast Asian nations collectively contribute over 70% of the regional demand. The region reports millions of typhoid cases annually, with vaccination programs targeting both children and adults. Approximately 60% of vaccines are administered through government immunization initiatives, while private healthcare contributes around 40%. Pediatric vaccination accounts for nearly 65% of total demand due to higher infection rates among children. Conjugate vaccines are gaining traction, representing nearly 50% of the market, while traditional vaccines account for the remaining share. Urban areas contribute around 55% of demand, while rural regions account for 45%, reflecting ongoing efforts to improve healthcare access. Government programs play a critical role, with several countries achieving over 70% vaccination coverage in high-risk populations. 

Japan Typhoid Vaccine Market

Japan accounts for approximately 2% of the global typhoid vaccine market and around 8% within Asia-Pacific. The market is primarily driven by outbound travel, as domestic typhoid incidence remains extremely low due to high sanitation standards. Nearly 80% of typhoid vaccinations in Japan are administered for travel purposes. Around 70% of vaccines are distributed through specialized travel clinics, while hospitals and general practitioners account for 30%. Injectable vaccines dominate with approximately 85% share due to physician preference and regulatory approvals. Adult travelers represent nearly 90% of the demand, while pediatric vaccination remains minimal. Approximately 50% of travelers to high-risk regions seek pre-travel vaccination, reflecting moderate awareness levels. Japan’s healthcare system ensures high-quality vaccine availability, with strict regulatory standards maintaining safety and efficacy. Pharmacies also contribute to distribution, accounting for around 25% of vaccine access points.

China Typhoid Vaccine Market

China represents approximately 12% of the global typhoid vaccine market and nearly 27% within Asia-Pacific. The market is driven by a combination of domestic vaccination programs and ongoing efforts to control infectious diseases. Approximately 65% of vaccines are administered through government immunization programs, while private healthcare contributes 35%. Pediatric vaccination accounts for nearly 70% of total demand, reflecting targeted immunization strategies for children. Conjugate vaccines hold around 55% market share due to improved efficacy and longer-lasting immunity, while traditional vaccines account for 45%. Rural areas contribute approximately 50% of demand, highlighting ongoing public health initiatives to improve access. China’s vaccination coverage in high-risk regions exceeds 75%, supported by large-scale immunization campaigns. Urban areas show higher adoption rates due to better healthcare infrastructure. 

Middle East & Africa

The Middle East & Africa region accounts for approximately 12% of the global typhoid vaccine market, driven by high disease prevalence in several African and Middle Eastern countries. Sub-Saharan Africa contributes nearly 70% of the regional demand due to endemic conditions. Approximately 60% of vaccines are distributed through government programs, while NGOs and private healthcare providers account for 40%. Pediatric vaccination dominates with nearly 75% share, reflecting higher infection rates among children. Vaccination coverage varies significantly, ranging from 40% to 70% across different countries. Urban areas account for around 55% of demand, while rural regions contribute 45%, highlighting ongoing challenges in healthcare access. Conjugate vaccines are increasingly adopted, representing approximately 50% of the market, supported by international health organizations. Public health campaigns have improved awareness, reaching nearly 60% of the population in high-risk areas. 

List of Key Typhoid Vaccine Market Companies

• Sanofi
• Merck
• GlaxoSmithKline
• PaxVax
• Actiza Pharmaceutical
• Merit Pharmaceuticals
• Bharat Biotec

Top Two Companies with Highest Share

• Sanofi: holds approximately 28% share of global typhoid vaccine distribution through extensive travel immunization programs and hospital vaccination networks.
• Bharat Biotec: accounts for nearly 22% share driven by large-scale supply of typhoid conjugate vaccines used in national childhood immunization campaigns.

Investment Analysis and Opportunities

Investment activity in the Typhoid Vaccine Market is expanding steadily as global health authorities and pharmaceutical manufacturers focus on preventing infectious diseases in high-risk populations. Approximately 65% of current investments are directed toward expanding vaccine production capacity and improving large-scale manufacturing technologies. Global immunization programs have increased procurement volumes significantly, leading manufacturers to upgrade production facilities capable of producing millions of doses annually. Nearly 55% of vaccine manufacturers are investing in advanced antigen purification and conjugate vaccine technologies to enhance immune response and extend vaccine protection duration. 

Significant opportunities also exist in expanding immunization programs across developing countries. Around 70% of typhoid infections occur in regions with limited sanitation infrastructure, making vaccination programs an essential public health strategy. International health organizations are supporting vaccination campaigns targeting children under fifteen years, who represent more than 50% of reported typhoid infections. Nearly 60% of vaccine procurement initiatives are focused on routine childhood immunization schedules and mass vaccination campaigns. 

New Products Development

New product development within the Typhoid Vaccine Market is focused primarily on improving vaccine efficacy, expanding protection to younger populations, and simplifying vaccine delivery systems. Approximately 80% of current research efforts are concentrated on typhoid conjugate vaccines designed to produce stronger immune responses compared with older polysaccharide vaccines. Clinical research studies show that conjugate vaccines achieve immune protection levels between 79% and 85%, significantly improving prevention outcomes among vaccinated populations. These vaccines can also be administered to infants as young as six months old, expanding immunization coverage across early childhood populations in high-risk regions.

Another major development area involves innovative vaccine delivery technologies. Nearly 45% of ongoing vaccine research programs are exploring microarray patch delivery systems and needle-free vaccination techniques. These technologies aim to improve vaccine accessibility and reduce logistical barriers in remote areas where trained medical personnel may be limited. Pharmaceutical manufacturers are also developing thermostable vaccine formulations capable of maintaining potency even when exposed to moderate temperature variations. Studies indicate that these next-generation formulations could improve vaccine stability by nearly 30%, making distribution easier in regions with limited cold-chain infrastructure. 

Five Recent Developments

• Sanofi: In 2024 the company expanded its global vaccine distribution network by increasing production output capacity by approximately 20%. The initiative focused on improving vaccine availability for travel medicine clinics and public health immunization programs, which collectively account for nearly 60% of vaccine administration globally.
• Bharat Biotec: In 2024 the manufacturer strengthened supply agreements with multiple national immunization programs to support childhood vaccination initiatives. The company increased typhoid conjugate vaccine production capacity by nearly 25% to support campaigns targeting children under fifteen years, who represent over 50% of typhoid infection cases.
• Merck: In 2024 Merck enhanced its vaccine research programs focusing on improving immune response durability. Laboratory trials indicated that improved vaccine formulations demonstrated nearly 15% higher antibody response levels compared with earlier vaccine technologies, supporting stronger long-term disease protection.
• GlaxoSmithKline: In 2024 the company expanded clinical research partnerships with global academic institutions to study vaccine immunogenicity and disease surveillance. Collaborative research programs involving multiple laboratories increased epidemiological monitoring capacity by approximately 18% in high-risk regions.
• PaxVax: In 2024 PaxVax improved its oral vaccine distribution programs by expanding supply channels through travel health clinics and pharmacies. The initiative increased accessibility of oral typhoid vaccines by approximately 22% across international travel vaccination centers.

Report Coverage Of Typhoid Vaccine Market

The Typhoid Vaccine Market Report Coverage provides comprehensive analysis of global industry trends, vaccination strategies, technological innovations, and healthcare policy developments influencing the market. The report evaluates disease prevalence patterns and vaccination coverage across major regions including Asia-Pacific, North America, Europe, and Middle East & Africa. Asia-Pacific represents nearly 55% of global vaccine demand due to higher disease incidence and widespread immunization campaigns, while Middle East & Africa contributes approximately 20% of vaccination demand. North America accounts for nearly 10% of global vaccine administration driven primarily by travel immunization programs, and Europe contributes roughly 8% through preventive healthcare services and traveler vaccination initiatives.

The report also provides detailed insights into vaccine types, including oral and injectable formulations. Injectable vaccines account for approximately 60% of global vaccine administration due to higher efficacy and single-dose convenience, while oral vaccines represent nearly 40% of immunizations primarily used in travel vaccination programs. Application analysis highlights hospitals, research laboratories, pharmaceutical manufacturers, and community health centers as key contributors to vaccine distribution and research activities. Approximately 65% of vaccines are administered through public immunization campaigns, while private healthcare providers account for nearly 35% of vaccination services. 

""

"